Raymond Wadlow

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

David A. Barbie, Pablo Tamayo, Jesse S. Boehm et al. · Nature · 2009 · 4.1K citations · Full text

Systems Biology, Oncogenic Agent, Medicine +4

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

Nanomedicine, Oncology, Pancreatic Cancer +8

Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

Claudia Scholl, Stefan Fröhling, Ian F. Dunn et al. · Cell · 2009 · 540 citations · Full text

Cell Regulation, Oncogenic Agent, Medicine +10

A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma

Theodore S. Hong, David P. Ryan, Darrell R. Borger et al. · International Journal of Radiation Oncology*Biology*Physics · 2014 · 113 citations · Full text

Phase 1/2, Proton Beam Therapy, Surgical Oncology +11

A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor

Jennifer A. Chan, Lawrence S. Blaszkowsky, Keith Stuart et al. · Cancer · 2013 · 90 citations · Full text